Literature DB >> 9649241

Predictors of outcome in emphysematous pyelonephritis.

Y L Wan1, S K Lo, M J Bullard, P L Chang, T Y Lee.   

Abstract

PURPOSE: We identified and quantified prognostic factors for emphysematous pyelonephritis.
MATERIALS AND METHODS: The clinical information, laboratory data and radiological findings from 38 patients with emphysematous pyelonephritis were retrospectively analyzed.
RESULTS: There were no significant differences between the nonsurvivor and survivor groups with respect to age, gender, diabetes mellitus history, presence of bacteremia, identity of infecting organisms, blood glucose level, leukocyte count, urinary white blood count, presence or absence of urinary tract obstruction or urolithiasis, and modes of treatment. There were significant differences between the nonsurvivor and survivor groups, however, with respect to platelet count (84,300 +/- 119,500 versus 220,400 +/- 161,800/mm.3, p = 0.001), serum creatinine level (3.61 +/- 1.25 versus 2.19 +/- 1.32 mg./dl., p = 0.003) and urinary red blood counts (56.47 +/- 41.86 versus 27.65 +/- 36.14, p = 0.028). Patients with radiological type I emphysematous pyelonephritis were significantly more likely to die than those with type II (69 versus 18%, p = 0.002).
CONCLUSIONS: Serum creatinine level is the most reliable predictor of outcome in patients with emphysematous pyelonephritis. By calculating likelihood ratios, patients with creatinine levels greater than 1.4 mg./dl. and platelet counts 60,000/mm.3 or less were at high risk. The posttest probability of death increased from 69 and 18% to 92 and 53% for type I and II emphysematous pyelonephritis, respectively. Patients with creatinine levels 1.4 mg./dl. or less and platelet counts greater than 60,000/mm.3 were at much lower risk. Posttest mortality risk in these patients dropped from 69 and 18% to 27 and 4% for type I and II emphysematous pyelonephritis, respectively.

Entities:  

Mesh:

Year:  1998        PMID: 9649241     DOI: 10.1016/s0022-5347(01)63919-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  28 in total

1.  A case of emphysematous pyelonephritis.

Authors:  Thomas Clark; Selma Fadul; Mei Abdalkareem; Khalid Ali
Journal:  J R Soc Med       Date:  2009-02       Impact factor: 5.344

2.  Emphysematous pyelonephritis with complete duplication of the left urinary tract.

Authors:  Yasuto Yamasaki; Shigehiko Koga; Yuzo Minami; Hideki Sakai
Journal:  Can Urol Assoc J       Date:  2011-12       Impact factor: 1.862

3.  Deriving a management algorithm for emphysematous pyelonephritis: Can we rely on minimally invasive strategies or should we be opting for earlier nephrectomy?

Authors:  Eve Boakes; Deepak Batura
Journal:  Int Urol Nephrol       Date:  2017-09-20       Impact factor: 2.370

4.  Risk factors for treatment failure in renal suppurative infections.

Authors:  Miroslav M Stojadinović; Sava R Mićić; Dragan R Milovanović; Slobodan M Janković
Journal:  Int Urol Nephrol       Date:  2008-08-15       Impact factor: 2.370

5.  Retrospective analysis of clinical profile prognostic factors and outcomes of 19 patients of emphysematous pyelonephritis.

Authors:  Ambar Khaira; Ankur Gupta; Devendra S Rana; Ashwini Gupta; Anil Bhalla; Dinesh Khullar
Journal:  Int Urol Nephrol       Date:  2009-04-30       Impact factor: 2.370

Review 6.  Current management of emphysematous pyelonephritis.

Authors:  Alan R Pontin; Richard D Barnes
Journal:  Nat Rev Urol       Date:  2009-05       Impact factor: 14.432

7.  Fever with abdominal pain and diabetes - Is it Emphysematous Pyelonephritis?

Authors:  Arvind Bamanikar; Swati Dhobale
Journal:  Malays J Med Sci       Date:  2014-05

8.  Role of Conservative Management in Emphysematous Pyelonephritis - A Retrospective Study.

Authors:  Sholay Meitei Kangjam; Keshorjit Singh Irom; Ibomcha Singh Khumallambam; Rajendra Singh Sinam
Journal:  J Clin Diagn Res       Date:  2015-11-01

9.  Risk of SOFA Deterioration in Conservative Treatment for Emphysematous Pyelonephritis: Pitfalls of Current Trends in Therapeutics from Multicenter Clinical Experience.

Authors:  Michinobu Ozawa; Osamu Ichiyanagi; Suguru Fujita; Sei Naito; Hiroki Fukuhara; Shinta Suenaga; Satoshi Takai; Takafumi Narisawa; Noriyuki Hosoya; Tatsuya Ishii; Takuya Yamanobe; Akinori Muto; Hitoshi Suzuki; Hayato Nishida; Tomoyuki Kato; Norihiko Tsuchiya
Journal:  Curr Urol       Date:  2019-05-10

10.  A case of emphysematous hepatitis with spontaneous pneumoperitoneum in a patient with hilar cholangiocarcinoma.

Authors:  Jung Ho Kim; Eul Sik Jung; Seok Hoo Jeong; Ju Seung Kim; Yang Suh Ku; Ki Baik Hahm; Ju Hyun Kim; Yeon Suk Kim
Journal:  Korean J Hepatol       Date:  2012-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.